LOMEFLOXACIN PHARMACOKINETICS IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL-FUNCTION

被引:20
作者
LEROY, A
FILLASTRE, JP
HUMBERT, G
机构
[1] UNIV ROUEN HAUTE NORMANDIE,HOP CHARLES NICOLLE,DEPT INFECT DIS,F-76031 ROUEN,FRANCE
[2] UNIV ROUEN HAUTE NORMANDIE,HOP CHARLES NICOLLE,DEPT NEPHROL,F-76031 ROUEN,FRANCE
关键词
D O I
10.1128/AAC.34.1.17
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Lomefloxacin pharmacokinetics were investigated in 6 normal subjects and 24 uremic patients after a single oral dose of 400 mg. In subjects with normal renal function, the peak level in plasma averaged 3.5 ± 0.9 μg/ml (mean ± standard deviation) and was obtained at 1.3 ± 0.9 h. The absorption rate constant was 3.8 ± 1.6 h-1. The terminal half-life was 7.77 ± 0.95 h. The apparent volume of distribution was 2.54 ± 0.66 liters/kg. Total body and renal clearances were 259 ± 83 and 200 ± 55 ml/min per 1.73 m2, respectively. The percentage of the dose recovered unchanged in 48-h urine was 80.6 ± 2.8. In uremic patients, the terminal half-life increased in relation to the degree of renal failure: from 8 h in normal subjects to 38 h in severely uremic patients (glomerular filtration rate, < 10 ml/min). Renal insufficiency did not significantly modify the peak level in plasma, the time to peak, the apparent volume of distribution, or the nonrenal clearance of lomefloxacin. The dialysis clearance of lomefloxacin was 54 ± 13 ml/min. Linear relationships were found between lomefloxacin pharmacokinetic parameters and glomerular filtration rate data. Dosage adjustments are necessary in uremic patients.
引用
收藏
页码:17 / 20
页数:4
相关论文
共 9 条
[1]   STATISTICAL ESTIMATIONS IN PHARMACOKINETICS [J].
BOXENBAU.HG ;
RIEGELMA.S ;
ELASHOFF, RM .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1974, 2 (02) :123-148
[2]   OFLOXACIN PHARMACOKINETICS IN RENAL-FAILURE [J].
FILLASTRE, JP ;
LEROY, A ;
HUMBERT, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (02) :156-160
[3]  
GOTCH FA, 1976, KIDNEY, P1672
[4]   DRUG-THERAPY - CLINICAL PHARMACOKINETICS .1. [J].
GREENBLATT, DJ ;
KOCHWESER, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 293 (14) :702-705
[5]   INVITRO AND INVIVO ACTIVITY OF NY-198, A NEW DIFLUORINATED QUINOLONE [J].
HIROSE, T ;
OKEZAKI, E ;
KATO, H ;
ITO, Y ;
INOUE, M ;
MITSUHASHI, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (06) :854-859
[6]   PHARMACOKINETICS AND TOLERANCE OF LOMEFLOXACIN AFTER SEQUENTIALLY INCREASING ORAL DOSES [J].
MORRISON, PJ ;
MANT, TGK ;
NORMAN, GT ;
ROBINSON, J ;
KUNKA, RL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (10) :1503-1507
[7]   CLINICAL PHARMACOKINETICS OF THE NEWER ANTIBACTERIAL 4-QUINOLONES [J].
NEUMAN, M .
CLINICAL PHARMACOKINETICS, 1988, 14 (02) :96-121
[8]   PHARMACOKINETICS AND TISSUE PENETRATION OF ORALLY-ADMINISTERED LOMEFLOXACIN [J].
STONE, JW ;
ANDREWS, JM ;
ASHBY, JP ;
GRIGGS, D ;
WISE, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (10) :1508-1510
[9]   INVITRO ACTIVITY OF LOMEFLOXACIN, A NEW QUINOLONE ANTIMICROBIAL AGENT, IN COMPARISON WITH THOSE OF OTHER AGENTS [J].
WISE, R ;
ANDREWS, JM ;
ASHBY, JP ;
MATTHEWS, RS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (05) :617-622